Nivolumab and Ipilimumab With or Without Sargramostim for Patients with Stage III-IV Melanoma

IRB/UVA Tracking #
18569
Contact First Name

Emily

Contact Last Name

Allred

Contact Email
Contact Phone
Official Trial Title
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Study Description

Nivolumab and Ipilimumab With or Without Sargramostim for Patients with Stage III-IV Melanoma

The University of Virginia Cancer Center Human Immune Therapy Center seeks men and women age 18 years and older to participate in a research study to learn more about the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with unresectable (cannot be removed by surgery) stage III-IV melanoma.

Monoclonal antibodies, such as ipilimumab and nivolumab, may kill tumor cells by blocking blood flow to the tumor, by stimulating white blood cells to kill the tumor cells, or by attacking specific tumor cells and stop them from growing or kill them. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.

There is no compensation for participating in this study.

For more information, or to see if you qualify to take part in this study, please contact:

Contact: Emily Allred
Phone: (434)982-1902
Email: eh4m@Virginia.EDU

Primary Investigator: Elizabeth Gaughan, MD
Accepts adult enrollment: Yes
IRB-HSR# 18569

Compensation

No Compensation